Noticias sector farmacéutico

Informes interesantes sobre Market Access de FirstWord

What should a next generation, fully optimised Market Access (MA) strategy actually look like? How are your MA strategies standing up to the scrutiny?

Lectura 2 minutos

8 de septiembre 2016

Comparte

What should a next generation, fully optimised Market Access (MA) strategy actually look like? How are your MA strategies standing up to the scrutiny?

Our latest report – The Future of Market Access – takes a closer look at this hot topic. Find out what experts in Europe and the US really think about how MA is evolving as a discipline and what opportunities there are left to stand out from the crowd.

Key takeaways include:

•	Don’t just consider the cost issues: Budget controls are a fact of life, but what else is significantly influencing market uptake?

•	Real world evidence is a real world problem: Are the right questions being answered (or asked)? What is the single, biggest issue?

•	Clearing the ‘fourth hurdle’: With multiple stakeholders, healthcare reforms, austerity challenges, plus a bureaucratic mountain to climb: how can you boost MA performance?

•	Joining the dots: When should MA planning begin? How much common ground is there? What elements do successful MA approaches share?

•	What next for HTAs?: Can (and should) Health Technology Assessment (HTA) requirements be harmonised? If so, who benefits?

Does your business have the right market access mindset? Sample the Insights

More reports like this:

The Cost of Specialty Drugs: Payer Perspectives

Based on in-depth interviews with 8 payers in the US and EU5, this report includes up-to-date views on the differences or similarities in approaches to managing specialty drug costs and the challenges faced by payers today. Read it to understand how the market is responding to rapidly rising specialty drug costs. See the top takeaways.

Innovations in Drug Pricing and Reimbursement

Public, health professional, political and payer hostility is growing worldwide as the prices of new drugs for chronic disease, specialty medicines and even generics grow excessively. How are payers in the US and Europe responding and what cost containment strategies could be used to cap unaffordable drug bills? See the top takeaways.

Customer Experience (CX) in Payer and Provider Engagement: How to Score Highly

A good payer CX goes way beyond price negotiation to really understanding and supporting payer decision-making and proving brand value. Pharma needs to walk the walk and not just talk the talk and this compelling new report provides a 360-degree analysis of the drivers and challenges for industry. See the top takeaways See the top takeaways.

Informes interesantes sobre Market Access de FirstWord

También te puede interesar

Barcelona acoge la II Edición de las Jornadas SaludONdigital

Pfizer propone esquemas de pago específicos para antibióticos

Farmaindustria lanza una certificación de su Código de Buenas Prácticas

Novo Nordisk: mentalidad circular hacia un impacto medioambiental cero

Suscríbete a la Newsletter